
    
      Participants randomized to ARM A will receive modified FOLFOX 7 every other week + MK-0646
      every week:

      5-FU 400 mg/m2 by intravenous infusion over 2-5 minutes Leucovorin 400 mg/m2 by intravenous
      infusion over 2 hours Oxaliplatin 85 mg/m2 by intravenous infusion over 2 hours (with
      leucovorin) Bevacizumab 5 mg/kg by intravenous infusion over 30 minutes (+/- 15 minutes)
      following infusions may be given over 10 minutes (+/- 10 minutes) if the first infusion is
      tolerated well.

      5-FU 2400 mg/m2 by continuous intravenous infusion over 46 hours (may be delivered via
      automated outpatient pump) Antiemetics (drugs that prevent nausea and vomiting): 5-HT3
      receptor antagonist (e.g. ondansetron) and dexamethasone are recommended prior to
      chemotherapy.

      MK-0646 10 mg/kg by intravenous infusion over 60 minutes every week (participants larger than
      100 kg [220 pounds] will receive their infusions over 120 minutes).

      Participants randomized to ARM B will receive modified FOLFOX 7 every other week + placebo
      every week:

      5-FU 400 mg/m2 by intravenous infusion over 2-5 minutes Leucovorin 400 mg/m2 by intravenous
      infusion over 2 hours Oxaliplatin 85 mg/m2 by intravenous infusion over 2 hours (with
      leucovorin) Bevacizumab 5 mg/kg by intravenous infusion over 30 minutes (+/- 15 minutes);
      following infusions may be given over 10 minutes (+/- 10 minutes) if the first infusion is
      tolerated well.

      5-FU 2400 mg/m2 by continuous intravenous infusion over 46 hours (may be delivered via
      automated outpatient pump) Antiemetics: 5-HT3 receptor antagonist (e.g. ondansetron) and
      dexamethasone are recommended prior to chemotherapy Placebo by intravenous infusion over 60
      minutes every week (participants larger than 100 kg [220 pounds] will receive their infusions
      over 120 minutes).
    
  